| DIRECT COMPETITOR COMPARISON | |
| TECH | Pvt1 | LIFE | MIL | Industry | | Market Cap: | 2.53B | N/A | 8.91B | 3.77B | 100.26M | | Employees: | 687 | N/A | 9,700 | 5,900 | 65 | | Qtrly Rev Growth (yoy): | -4.00% | N/A | 121.40% | 4.30% | 19.70% | | Revenue (ttm): | 261.17M | 1.03B1 | 2.95B | 1.63B | 14.05M | | Gross Margin (ttm): | 78.83% | N/A | 64.07% | 55.30% | 65.67% | | EBITDA (ttm): | 156.58M | N/A | 818.22M | 402.43M | -12.30M | | Oper Margins (ttm): | 56.95% | N/A | 15.72% | 16.93% | -137.11% | | Net Income (ttm): | 103.42M | N/A | 7.87M | 172.38M | N/A | | EPS (ttm): | 2.754 | N/A | 0.049 | 3.081 | -0.32 | | P/E (ttm): | 24.62 | N/A | 1019.39 | 22.02 | 16.37 | | PEG (5 yr expected): | 2.08 | N/A | 1.48 | 1.42 | 1.31 | | P/S (ttm): | 9.68 | N/A | 3.08 | 2.34 | 9.43 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.42 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | LIFE | | InvestorSoup.com Issues Technical Trading Outlook for ARCA biopharma Inc.
Wed, Nov 25 -
GlobeNewswire | | • | MIL | | MIL Buys Remaining Stake in India
Tue, Nov 24 -
Zacks.com | | • | MIL | | Millipore buys full stake in India joint venture
Mon, Nov 23 -
AP | | • | MIL | | Millipore Acquires Remaining Ownership of its Joint-Venture in India
Mon, Nov 23 -
Business Wire | | • | LIFE | | Uncertainty Breeds Opportunity in Specialty Pharma Stock Pick From Piper Jaffray Senior Research Analyst
Fri, Nov 20 -
Wall Street Transcript | | • | LIFE | | Beacon Equity Issues Technical Trading Overview for Questcor Pharmaceuticals Inc.
Thu, Nov 19 -
GlobeNewswire | | • | MIL | | MILLIPORE CORP /MA Financials
Sat, Nov 14 -
EDGAR Online Financials | | • | LIFE | | LIFE TECHNOLOGIES CORP Files SEC form 8-K, Unregistered Sale of Equity Securities
Fri, Nov 13 -
EDGAR Online | | • | LIFE | | Desktop Bug Detector
Thu, Nov 12 -
at Forbes.com | | • | MIL | | Millipore Corporation named Corporate Citizen of the Year
Thu, Nov 12 -
Business Wire | | • | MIL | | MILLIPORE CORP /MA Files SEC form 10-Q, Quarterly Report
Tue, Nov 10 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
Competitors
